Clinical Trials

Clinical Trials

We believe that addressing the disruption of the intestinal barrier can fundamentally change the way diseases are treated and establish new standards of patient care.

Clinical-Shield

Post-Surgical Intraabdominal Adhesions

Ongoing Phase 2 study to evaluate LB1148 for its effect on post-operative ileus and intra-abdominal adhesions and return of gastrointestinal function in subjects undergoing elective bowel resection (PROFILE)

Randomized, Double-Blind, Placebo-Controlled, Multi-Site Study
Up to 200 patients ∣ ~70 patients with a planned adhesion evaluation ∣ ～17 sites in the U.S.

Evaluate LB1148 to reduce the formation of post-surgical intra-abdominal adhesions and accelerate the return of GI function in subjects undergoing elective bowel resection with planned stoma take-down

Primary Endpoint: Extent and severity of adhesions score

For complete study details, please view the study listing on clinicaltrials.gov: NCT02836470

LB1148 Reduced Adhesion Formation in GI Surgery Patients

If you are interested in learning more about our clinical trials, please contact Palisade Bio at:
info@palisadebio.com or 858.704.4900